Quick Answer
Fulgent Genetics, Inc. reported Cash and Equivalents of $50.19 million for fiscal year 2025.
Fulgent Genetics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $50.19M | -9.0% |
| 2024 | $55.14M | -43.4% |
| 2023 | $97.47M | +22.6% |
| 2022 | $79.51M | -51.8% |
| 2021 | $164.89M | +88.6% |
| 2020 | $87.43M | +630.7% |
| 2019 | $11.96M | +77.6% |
| 2018 | $6.74M | +3.8% |
| 2017 | $6.49M | -17.8% |
| 2016 | $7.90M | +1514.9% |
| 2015 | $489.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $117.64M | +102.7% | +33.9% |
| June 30, 2025 | $87.88M | +35.0% | +30.6% |
| March 31, 2025 | $67.28M | +23.1% | +22.0% |
| December 31, 2024 | $55.14M | -43.4% | -5.0% |
| September 30, 2024 | $58.04M | -31.0% | -10.9% |
| June 30, 2024 | $65.11M | +11.6% | +19.1% |
| March 31, 2024 | $54.68M | -17.4% | -43.9% |
| December 31, 2023 | $97.47M | +22.6% | +15.9% |
- Fulgent Genetics, Inc. showed a decrease of -9.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2015–2025 period, Fulgent Genetics, Inc.’s cash and equivalents has grown by 10164.4% (from $489.0 thousand to $50.19 million).
- The most recent figure is from Fulgent Genetics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: